These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 30341384)
1. Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations. Leontiadou H; Galdadas I; Athanasiou C; Cournia Z Sci Rep; 2018 Oct; 8(1):15544. PubMed ID: 30341384 [TBL] [Abstract][Full Text] [Related]
2. A novel carcinogenic PI3Kα mutation suggesting the role of helical domain in transmitting nSH2 regulatory signals to kinase domain. Ghalamkari S; Alavi S; Mianesaz H; Khosravian F; Bahreini A; Salehi M Life Sci; 2021 Mar; 269():118759. PubMed ID: 33189828 [TBL] [Abstract][Full Text] [Related]
3. Regulation of lipid binding underlies the activation mechanism of class IA PI3-kinases. Hon WC; Berndt A; Williams RL Oncogene; 2012 Aug; 31(32):3655-66. PubMed ID: 22120714 [TBL] [Abstract][Full Text] [Related]
4. Assessing the subcellular distribution of oncogenic phosphoinositide 3-kinase using microinjection into live cells. Layton MJ; Rynkiewicz NK; Ivetac I; Horan KA; Mitchell CA; Phillips WA Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919038 [TBL] [Abstract][Full Text] [Related]
5. Cryo-EM structures of cancer-specific helical and kinase domain mutations of PI3Kα. Liu X; Zhou Q; Hart JR; Xu Y; Yang S; Yang D; Vogt PK; Wang MW Proc Natl Acad Sci U S A; 2022 Nov; 119(46):e2215621119. PubMed ID: 36343266 [TBL] [Abstract][Full Text] [Related]
6. Comparative molecular dynamics analyses on PIK3CA hotspot mutations with PI3Kα specific inhibitors and ATP. Menteş M; Karakuzulu BB; Uçar GB; Yandım C Comput Biol Chem; 2022 Aug; 99():107726. PubMed ID: 35842959 [TBL] [Abstract][Full Text] [Related]
7. Oncogenic mutations weaken the interactions that stabilize the p110α-p85α heterodimer in phosphatidylinositol 3-kinase α. Echeverria I; Liu Y; Gabelli SB; Amzel LM FEBS J; 2015 Sep; 282(18):3528-42. PubMed ID: 26122737 [TBL] [Abstract][Full Text] [Related]
8. Role of E542 and E545 missense mutations of PIK3CA in breast cancer: a comparative computational approach. Thirumal Kumar D; George Priya Doss C J Biomol Struct Dyn; 2017 Sep; 35(12):2745-2757. PubMed ID: 27581627 [TBL] [Abstract][Full Text] [Related]
9. The structural basis for Ras activation of PI3Kα lipid kinase. Zhang M; Jang H; Nussinov R Phys Chem Chem Phys; 2019 Jun; 21(22):12021-12028. PubMed ID: 31135801 [TBL] [Abstract][Full Text] [Related]
10. Calmodulin (CaM) Activates PI3Kα by Targeting the "Soft" CaM-Binding Motifs in Both the nSH2 and cSH2 Domains of p85α. Zhang M; Li Z; Wang G; Jang H; Sacks DB; Zhang J; Gaponenko V; Nussinov R J Phys Chem B; 2018 Dec; 122(49):11137-11146. PubMed ID: 30047727 [TBL] [Abstract][Full Text] [Related]
11. Double Vasan N; Razavi P; Johnson JL; Shao H; Shah H; Antoine A; Ladewig E; Gorelick A; Lin TY; Toska E; Xu G; Kazmi A; Chang MT; Taylor BS; Dickler MN; Jhaveri K; Chandarlapaty S; Rabadan R; Reznik E; Smith ML; Sebra R; Schimmoller F; Wilson TR; Friedman LS; Cantley LC; Scaltriti M; Baselga J Science; 2019 Nov; 366(6466):714-723. PubMed ID: 31699932 [TBL] [Abstract][Full Text] [Related]
12. Investigating the structure and dynamics of the PIK3CA wild-type and H1047R oncogenic mutant. Gkeka P; Evangelidis T; Pavlaki M; Lazani V; Christoforidis S; Agianian B; Cournia Z PLoS Comput Biol; 2014 Oct; 10(10):e1003895. PubMed ID: 25340423 [TBL] [Abstract][Full Text] [Related]
13. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Huang CH; Mandelker D; Schmidt-Kittler O; Samuels Y; Velculescu VE; Kinzler KW; Vogelstein B; Gabelli SB; Amzel LM Science; 2007 Dec; 318(5857):1744-8. PubMed ID: 18079394 [TBL] [Abstract][Full Text] [Related]
14. Molecular Mechanisms of Human Disease Mediated by Oncogenic and Primary Immunodeficiency Mutations in Class IA Phosphoinositide 3-Kinases. Dornan GL; Burke JE Front Immunol; 2018; 9():575. PubMed ID: 29616047 [TBL] [Abstract][Full Text] [Related]
15. The E545K mutation of PIK3CA promotes gallbladder carcinoma progression through enhanced binding to EGFR. Zhao S; Cao Y; Liu SB; Wang XA; Bao RF; Shu YJ; Hu YP; Zhang YJ; Jiang L; Zhang F; Liang HB; Li HF; Ma Q; Xu Y; Wang Z; Zhang YC; Chen L; Zhou J; Liu YB J Exp Clin Cancer Res; 2016 Jun; 35(1):97. PubMed ID: 27317099 [TBL] [Abstract][Full Text] [Related]
17. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoinositide 3-kinase p110α (PIK3CA). Burke JE; Perisic O; Masson GR; Vadas O; Williams RL Proc Natl Acad Sci U S A; 2012 Sep; 109(38):15259-64. PubMed ID: 22949682 [TBL] [Abstract][Full Text] [Related]
18. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755 [TBL] [Abstract][Full Text] [Related]
19. Biophysical aspect of phosphatidylinositol 3-kinase and role of oncogenic mutants (E542K & E545K). Kalsi N; Gopalakrishnan C; Rajendran V; Purohit R J Biomol Struct Dyn; 2016 Dec; 34(12):2711-2721. PubMed ID: 26646651 [TBL] [Abstract][Full Text] [Related]
20. A frequent kinase domain mutation that changes the interaction between PI3Kalpha and the membrane. Mandelker D; Gabelli SB; Schmidt-Kittler O; Zhu J; Cheong I; Huang CH; Kinzler KW; Vogelstein B; Amzel LM Proc Natl Acad Sci U S A; 2009 Oct; 106(40):16996-7001. PubMed ID: 19805105 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]